Literature DB >> 12480676

Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis.

H Marzo-Ortega1, D McGonagle, P O'Connor, P Emery.   

Abstract

The seronegative spondyloarthropathies (SpAs) are associated both with clinical and subclinical colitis. Recently biological blockade with the tumour necrosis factor alpha (TNFalpha) antagonists infliximab and etanercept has been shown to be effective in the treatment of SpA. However, only infliximab is efficacious in the treatment of colitis in patients with Crohn's SpA. We report on two patients with SpA and associated Crohn's disease treated with etanercept whose arthritis showed an excellent response with complete resolution of spinal pathology, whereas their Crohn's disease persisted or flared. These findings suggest that the effect of TNFalpha blockade in SpA differs between the joint and the bowel.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12480676      PMCID： PMC1754306          DOI： 10.1136/ard.62.1.74

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  31 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 2.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

Review 3.  [Anti-TNF-α treatment for uveitis. Analysis of the current situation].

Authors:  U Pleyer; F Mackensen; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

Review 4.  The treatment of the rheumatological manifestations of the inflammatory bowel diseases.

Authors:  Melissa Padovan; Gabriella Castellino; Marcello Govoni; Francesco Trotta
Journal:  Rheumatol Int       Date:  2006-06-24       Impact factor: 2.631

Review 5.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 6.  Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors:  Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2020-07-13       Impact factor: 20.543

7.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 8.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

9.  [Update: enterogenic spondylarthritis].

Authors:  Elisabeth Märker-Hermann
Journal:  Z Rheumatol       Date:  2021-05-27       Impact factor: 1.372

10.  A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations.

Authors:  Filip Van den Bosch
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.